Reply
We thank Dr Bhathena 1 for his interest in our recent review article. 2 The purpose of the review was to highlight the many different indications in gynaecological practice, in which progesterone receptor modulators (PRMs) may be applied and to focus on the potential health benefits of PRMs. PRMs have an endometrial antiproliferative effect in the presence of follicular phase estrogen levels, and this constitutes the basis of many of their potential advantages in the management of gynaecological conditions. Currently, the only licensed indications for PRMs [mifepristone for termination of pregnancy and ulipristal (UPA) for emergency contraception (EC)] both relate to fertility control. Ulipristal has only recently received a licence based on good evidence regarding its effectiveness for EC even when taken up to 120 hours after intercourse. 3, 4 This Journal has previously published very informative commentaries and correspondence on the topic of UPA in emergency contraception. [5] [6] [7] Like other PRMs, UPA is associated with suppression of ovulation and menstruation via an effect, which may not be explained merely by progesterone antagonism. 8, 9 Registration of UPA followed the publication of the UPA trial and meta-analysis in the Lancet paper. 3 The authors of this paper pointed out that regarding the mechanism of action, an effect of UPA on the endometrium could not be ruled out although the effect on ovulation inhibition is potent. With respect to any potential harmful effect on pregnancy, it is reassuring to note that the rate of miscarriage between women treated with levonorgestrel and UPA for EC was not different. The Royal Charter of the Royal College of Obstetrician and Gynaecologists (RCOG) (1947) states the purpose is: "The encouragement of the study and the advancement of the science and practice of obstetrics and gynaecology". This is a broad definition and should allow the RCOG and the FSRH to take a progressive view of joint training.
In conclusion, I fully support the Personal View article and would be happy to discuss it further with the authors. I will also be interested to hear about future progress on this issue. We have a related issue at the moment and would welcome comment from other Journal readers. It concerns the Faculty's guidance on resuscitation for nurses when fitting IUDs. 2 It suggests someone competent to give intravenous (IV) drugs must be available. The Royal College of Nursing (RCN) has also made a statement 3 supporting this but when contacted the RCN said it supported it because it was Faculty guidance and didn't seem to understand the consequences or practicalities. It would appear that there is no named person to discuss this matter with there.
We currently have nurse-led community clinics that provide intrauterine devices/ intrauterine systems (IUDs/IUSs) with no doctor present. Indeed we have very few doctors in such clinics.
None of us have ever cannulated or given IV drugs (including me for over 20 years). Some people have taken blood from time to time but none of us have any need to do so regularly. We are advised that to be competent to do so would involve weekly IV drug administration/ cannulation, which would remove us all from clinic to theatre or similar to do so. Our resuscitation department is amazed by the guidance.
We surely cannot be the only family planning unit that has predominantly nurse-led clinics, and I cannot believe all IUD fitters have extensive
